Skip to main content

Celltrion

Celltrion, Inc. is a leading South Korean biotechnology and biopharmaceutical enterprise specializing in the research, development, and manufacturing of biosimilars and innovative monoclonal antibody therapies. The company operates across the entire biopharmaceutical value chain from cell line engineering and clinical development to large-scale manufacturing and global commercialization. Its principal business activities encompass biotechnology research, contract manufacturing of biological drugs, and the global distribution of biosimilar therapeutics targeting oncology and autoimmune diseases. Celltrion's main revenue drivers are international commercial sales of approved biosimilar products and biopharmaceutical contract manufacturing service fees. As a global pioneer in the biosimilars industry, the company holds a leading market position within the international healthcare sector. Headquartered in Incheon, South Korea, Celltrion is publicly listed and traded on the Korea Exchange.

21 of the funds FundTelligence covers report a position in Celltrion.

Sector
Health Care
Country
South Korea
Funds holding it
21

Funds holding Celltrion

Showing the 8 largest of 21 funds holding it.

Loading...